Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Many botanicals show potential for cancer chemoprevention but have failed in clinical trials.
• Systematic, molecular-target based approaches are crucial for evaluating botanical agents.
• Botanicals modulate key carcinogenesis pathways, including mutagenesis, proliferation, and apoptosis.

Purpose of the Study:

• To provide models for translational research on botanicals for cancer chemoprevention.
• To focus on targeted therapies for prostate cancer (PCa) chemoprevention.
• To outline requirements for advancing botanical agents to clinical recommendation.

Main Methods:

• Review of epidemiological, in vitro, and preclinical studies.
• Analysis of Phase I safety data.
• Consideration of biomarker-driven clinical trial design based on carcinogenesis pathways.

Main Results:

• Botanicals influence multiple biochemical and molecular cascades relevant to cancer prevention.
• These agents demonstrate a promising safety profile compared to conventional treatments.
• Evidence suggests botanicals can inhibit cancer formation and growth.

Conclusions:

• Translational research models are needed to bridge the gap between preclinical promise and clinical efficacy of botanicals.
• Rigorous, ethically sound clinical trials are paramount for validating botanical cancer chemopreventives.
• Botanicals hold significant potential for cancer prevention and treatment with favorable safety profiles, particularly for targeted therapies like PCa chemoprevention.